13
Participants
Start Date
May 31, 2009
Primary Completion Date
February 28, 2011
Study Completion Date
May 31, 2011
MGAWN1
Humanized monoclonal to West Nile virus. Dose = 30 mg/kg actual body weight intravenous, one dose at Day 0.
Placebo - normal saline
Normal Saline intravenous, volume same as active comparator, one dose at Day 0
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
MacroGenics
INDUSTRY